Engineering Protein-Based HIV Entry Inhibitors: Advances, Challenges, and Translational Strategies
Biomolecules · 2026
DOI: 10.3390/biom16091221 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2026. Verfasst von Rashmi Kumariya und 1 weiteren Autor:innen. Beteiligte Einrichtung: Natural Products Chemistry Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National In…. Hauptthemen laut MEDLINE: HIV Infections, Protein Engineering, Virus Internalization, HIV Fusion Inhibitors. Die Arbeit nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NIDDK NIH HHS, Office of AIDS Research.
Abstract (Originalsprache)
Human immunodeficiency virus (HIV) is an enveloped virus with a remarkable capacity for genetic diversification, enabling rapid escape from host immune responses and therapeutic interventions. Despite extensive global efforts, the development of an effective vaccine has remained elusive owing to the virus’s high genetic variability and antigenic diversity. Consequently, considerable effort has been directed toward the development of therapeutic agents targeting viral entry, reverse transcriptase, integrase, protease, and more recently, capsid. Although antiretroviral therapy (ART) remains the cornerstone of HIV treatment, it is associated with challenges including drug resistance, adverse side effects, and limitations in access and affordability. Targeting viral entry offers distinct advantages by blocking infection at the earliest stage of the viral life cycle and enabling the neutralization of free virions, as well as Fc-mediated elimination of HIV-infected cells in some cases. This review highlights promising protein-based HIV entry inhibitors that have demonstrated efficacy in preclinical studies, and discusses ongoing efforts to optimize their valency, avidity, specificity, serum half-life, effector functions, and production platforms to improve their therapeutic potential and economic feasibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Natural Products Chemistry Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Förderung
- Intramural NIH HHS
- NIDDK NIH HHS
- Office of AIDS Research
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Kumariya, R., & Bewley, C. A. (2026). Engineering Protein-Based HIV Entry Inhibitors: Advances, Challenges, and Translational Strategies. Biomolecules. https://doi.org/10.3390/biom16091221
Vancouver
Kumariya R, Bewley CA. Engineering Protein-Based HIV Entry Inhibitors: Advances, Challenges, and Translational Strategies. Biomolecules. 2026. doi:10.3390/biom16091221
BibTeX
@article{Kumariya2026,
author = {Kumariya, Rashmi and Bewley, Carole A},
title = {Engineering Protein-Based HIV Entry Inhibitors: Advances, Challenges, and Translational Strategies},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16091221}
}
EUVIMED